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Mouse aorta-derived mesenchymal progenitor
cells contribute to and enhance the immune
response of macrophage cells under
inflammatory conditions
Jodi F Evans1,2*, Veronica Salvador1, Sheela George1, Cristina Trevino-Gutierrez1,3 and Catherine Nunez1,3
Abstract
Introduction: Mesenchymal progenitor cells interact with immune cells and modulate inflammatory responses. The
cellular characteristics required for this modulation are under fervent investigation. Upon interaction with
macrophage cells, they can contribute to or suppress an inflammatory response. Current studies have focused on
mesenchymal progenitors derived from bone marrow, adipose, and placenta. However, the arterial wall contains
many mesenchymal progenitor cells, which during vascular disease progression have the potential to interact with
macrophage cells. To examine the consequence of vascular-tissue progenitor cell-macrophage cell interactions in
an inflammatory environment, we used a recently established mesenchymal progenitor cell line derived from the
mouse aorta.
Methods: Mouse bone marrow-derived macrophage (MΦ) cells and mouse aorta-derived mesenchymal progenitor
(mAo) cells were cultured alone or co-cultured directly and indirectly. Cells were treated with oxidized low-density
lipoprotein (ox-LDL) or exposed to the inflammatory mediators lipopolysaccharide (LPS) and interferon-gamma
(IFNγ) or both. A Toll-like receptor-4 (TLR4)-deficient macrophage cell line was used to determine the role of the
mAo cells. To monitor inflammation, nitric oxide (NO), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNFα)
secretions were measured.
Results: Mesenchymal progenitor cells isolated from aorta and cloned by high proliferative capacity (mAo) can
differentiate into multiple mesenchymal lineages and are positive for several commonly used mouse mesenchymal
stem cell markers (that is, CD29, CD44, CD105, CD106, and Sca-1) but are negative for CD73 and ecto-5′-nucleotidase.
In co-culture with MΦ cells, they increase MΦ oxidized-LDL uptake by 52.2%. In an inflammatory environment, they
synergistically and additively contribute to local production of both NO and IL-6. After exposure to ox-LDL, the
inflammatory response of MΦ cells to LPS and LPS/IFNγ is muted. However, when lipid-laden MΦ cells are co-cultured
with mAo cell progenitors, the muted response is recovered and the contribution by the mAo cell progenitor is
dependent upon cell contact.
Conclusions: The resident mesenchymal progenitor cell is a potential contributor to vascular inflammation when in
contact with inflamed and lipid-laden MΦ cells. This interaction represents an additional target in vascular disease
treatment. The potential for resident cells to contribute to the local immune response should be considered when
designing therapeutics targeting inflammatory vascular disease.
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Introduction
Mesenchymal progenitor cells have the capacity for tis-
sue repair through direct differentiated cell replacement
and also the ability to regulate immune responses during
inflammation [1,2]. In immune studies, mesenchymal
progenitors isolated from bone marrow, adipose tissue,
and placenta have received the most attention. These
progenitor populations can suppress T-cell proliferation,
induce regulatory T cells, and promote the differenti-
ation of the anti-inflammatory macrophage [3-5]. How-
ever, mesenchymal stem cells (MSCs) and progenitor
cells are present in the arterial wall [6] and the role these
tissue-specific cells play in vascular inflammation and
disease remains unclear [7].
During vascular inflammation, monocytes enter the ar-
tery wall in response to activated endothelium and dif-
ferentiate into macrophages. Macrophage cells that have
entered the sub-endothelium play a role in both inflam-
mation and resolution of inflammation in the vascula-
ture [8]. The traditionally activated macrophage (M1),
differentiated in the presence of inflammatory mediators
such as lipopolysaccharide (LPS) and interferon-gamma
(IFNγ), is pro-inflammatory and contributes to local pro-
duction of inflammatory cytokines such as interleukin-12
(IL-12), tumor necrosis factor-alpha (TNFα), and IL-6 [9].
Macrophage cells also ingest lipoproteins in the form of
oxidized low-density lipoprotein (ox-LDL) that have been
retained in the sub-endothelium. These lipid-laden macro-
phage cells or ‘foam cells’ are associated with an inflam-
matory response that leads to the attraction of additional
monocytes as well as T cells and mast cells [8]. However,
the alternatively activated macrophage phenotype (M2) is
associated with increased expression of anti-inflammatory
cytokines such as IL-10 and acts in resolution of inflam-
mation and tissue repair [10,11].
Like macrophage cells, mesenchymal progenitor cells
can experience phenotypic polarization and display an
immunosuppressive or pro-inflammatory phenotype
[12]. Immunosuppressive mesenchymal progenitor cells
promote a ‘switch’ in the macrophage cell phenotype
from the inflammatory M1 to the anti-inflammatory M2
[3-5]. Conversely, some studies report that mesenchymal
progenitors display a pro-inflammatory phenotype when
cultured with macrophage cells [13]. During their differ-
entiation, sub-endothelial macrophages and foam cells
come in contact with the many mesenchymal progeni-
tors in the arterial wall. Here, we sought to determine
whether the interaction between aorta-derived mesen-
chymal progenitor cells and macrophages has the poten-
tial to contribute to or suppress inflammation in an
environment associated with vascular disease.
Mouse bone marrow-derived macrophage (MΦ) cells
and a recently established mouse aorta-derived mesen-
chymal progenitor (mAo) cell line [14] were cultured
alone or co-cultured directly and indirectly. The cells
were treated with ox-LDL or exposed to the inflamma-
tory mediators LPS and IFNγ or both. A Toll-like
receptor-4-deficient macrophage (TLR4-MΦ) cell line
was used to determine the role of the mAo cells in the
inflammatory response. To monitor inflammation, nitric
oxide (NO), IL-6, and TNFα secretions were measured.
Methods
Materials
All cell culture media, trypsin, fetal bovine serum (FBS),
and antibiotic/antimycotic solutions were obtained from
Invitrogen (Carlsbad, CA, USA). The L-929 fibroblast
(CCl-1), LADMAC macrophage/monocyte (CRL-2420),
and C3H/HeJ mouse I-13.35 splenic cell lines (CRL-
2471) deficient for TLR-4 were purchased from the
American Type Tissue Collection (ATCC) (Manassas,
VA, USA). Endotoxin tested (less than 0.1 ng/μg) IFNγ
(#I1000) was purchased from US Biological (Salem, MA,
USA), the inducible nitric oxide synthase (iNOS)
(#2977) antibody from Cell Signaling Technology (Dan-
vers, MA, USA), the anti-monocyte/macrophage anti-
body (MOMA-2, ab33451) and anti-integrin beta-1
antibody (CD29) (#ab23834) from Abcam (Cambridge,
MA, USA), and the fluorescein isothiocyanate (FITC) rat
anti-mouse CD44 (#553133), phycoerythrin (PE) rat
anti-mouse CD105 (#562759), PE rat anti-mouse Ly-
6AE (Sca-1) (#561076), FITC rat anti-mouse CD45
(#553080), FITC rat anti-mouse CD106 (#553332), PE
rat anti-mouse CD73 (#557041), and FITC rat anti-
mouse CD11b (#553310) were purchased from BD Bio-
sciences (San Jose, CA, USA). Human ox-LDL was pur-
chased from Intracel (Frederick, MD, USA). Gamma-
irradiated LPS from Escherichia coli (#L4391) and all
other chemicals and reagents were purchased from
Sigma-Aldrich (St. Louis, MO, USA) unless otherwise
specified.
Animals
All animal protocols were approved by the Winthrop
University-Hospital Animal Care and Use Committee
and adhere to the regulations outlined by the National
Institutes of Health. C57BL/6 male mice were obtained
from Taconic (Hudson, NY, USA). Animals were housed
under local vivarium conditions (12-hour light-dark
cycle) and allowed to acclimate for at least 7 days prior
to experimentation. Mice were euthanized under CO2 at
8 to 12 weeks of age, and aorta and hind limbs were re-
moved in preparation for cell isolation.
Cell isolation and culture
Aortic mesenchymal progenitor (mAo) cell line
Mouse aortic progenitor cells were derived from the
C57BL/6 mouse by using the method of da Silva and
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colleagues [6] with slight modification as described
in [14].
Bone marrow-derived macrophage (MΦ) cells
Bone marrow from the hind limbs of the C57BL/6
mouse was isolated as previously described [15]. After a
single-cell suspension was created, nucleated cells were
counted by using 3% acetic acid/trypan blue exclusion
and plated in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% FBS, 15% L929 fibro-
blast cell conditioned medium, 100 U/mL penicillin so-
dium, 100 U/mL streptomycin sulfate, and 0.25 μg/mL
amphotericin B at 107 cells per 100-mm petri dish. The
L929 conditioned medium was prepared as suggested by
the ATCC. The L-929 cell line produces macrophage
colony-stimulating factor (M-CSF), which supports the
growth and differentiation of macrophages from the
bone marrow. After 3 days, half the medium was re-
moved and replaced with fresh medium. A complete
medium change was performed on day 6. At day 7 of
culture, monocyte/macrophage cells were re-plated ac-
cording to experimental objectives, passed or frozen,
and stored in liquid nitrogen (LN2). Cultures up to pas-
sage 2 were used in experiments.
C3H/HeJ mouse I-13.35 splenic macrophage (TLR4-MΦ) cell
line
The I-13.35 cell line is deficient in TLR-4 and was main-
tained in DMEM supplemented with 10% FBS, 20%
LADMAC cell conditioned medium, 100 U/mL penicillin
sodium, 100 U/mL streptomycin sulfate, and 0.25 μg/mL
amphotericin B. The LADMAC conditioned medium was
prepared as suggested by the ATCC. The LADMAC cells
produce colony-stimulating factor 1 (CSF-1)/M-CSF which
supports the growth of the TLR4-MΦ cell line. Cultures
were initiated at 105 per mL in 24-well plates or 60-mm
dishes with and without a confluent layer of mAo cells
according to experimental objectives.
Co-culture
The mAo cells were initiated at a density of 1.5 × 104/
cm2 and allowed to reach confluence. MΦ or TLR4-MΦ
cells were added at a density of 1.0 × 105/cm2 and
allowed to attach overnight. Cultures were left untreated,
treated with LPS (100 ng/mL), or treated with both LPS
and IFNγ (250 ng/mL) for 24 hours. Some cultures were
exposed to ox-LDL (50 μg/mL) overnight prior to expos-
ure to inflammatory mediators. Culture supernatants
were collected and stored at −80°C until assay.
Transwell cultures
For assays using transwell culture, MΦ cells were seeded
at a density of 1.0 × 105/cm2 in a transwell insert with a
0.4-μm pore-size filter and treated 24 hours with or
without 50 μg/mL ox-LDL. mAo MSCs were seeded in
the well at a density of 1.5 × 104/cm2. Media in both the
insert and well were left untreated, treated with LPS
(100 ng/mL), or treated with both LPS and IFNγ
(250 ng/mL) for 24 hours. Media from both insert and
well were collected and assayed separately.
Conditioned medium cultures
For conditioned medium experiments, the conditioned
medium was collected from mAo or MΦ cell cultures
that had been treated with ox-LDL (50 μg/mL) for
24 hours and then treated with LPS (100 ng/mL) or
treated with both LPS and IFNγ (250 ng/mL) for
24 hours. The conditioned medium was incubated with
mAo or MΦ cell cultures that had been exposed to ox-
LDL. After 24 hours, the incubated medium was col-
lected, and NO, IL-6, and TNFα were measured. NO,
IL-6, and TNFα present in the conditioned medium
were subtracted from the incubated medium values to
obtain the net production.
Flow cytometry
For staining of mAo cell surface antigens, single-cell sus-
pensions were first incubated with Fc receptor blocking
reagent (Miltenyi Biotech, Bergisch Gladbach, Germany)
followed by staining with antibodies against surface
markers CD11b, CD29, CD44, CD45, CD73, CD105,
CD106, Sca-1 (Ly-6AE), and CD45 for 30 minutes at 4°C.
After incubation, cells were washed twice in wash buffer
(1% FBS in phosphate-buffered saline, or PBS) and ana-
lyzed with an Accuri C6 flow cytometer (BD Biosciences).
For intracellular MOMA-2 staining of monocyte/
macrophage cultures, cells were fixed and permeabilised
by using the Fix and Perm Kit (Invitrogen) in accordance
with the protocol of the manufacturer. Briefly, the cells
were fixed with buffer A for 15 minutes at room
temperature and washed once with wash buffer. Fixed
cells were permeabilised with buffer B for 20 minutes
at room temperature, and intracellular staining anti-
bodies were added simultaneously. After incubation,
cells were washed twice in wash buffer and analyzed
with the flow cytometer. Flow cytometry data was ana-
lyzed by using FlowJo software (Tree Star Inc., Ashland,
OR, USA).
Oil Red O staining
After fixing in 10% phosphate-buffered formalin, cul-
tures were rinsed in PBS, air-dried, and stained with Oil
Red O (0.5 g in 100 mL isopropanol) for 15 minutes.
Wells were extensively washed with dH2O followed by
imaging and removal of stain by using 100% isopropanol.
The amount of stain was quantified by using spectro-
photometry at a 550-nm wavelength.
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Alcian blue/von Kossa staining
mAo cells were grown in chondrogenic medium—DMEM
supplemented with 1% insulin-transferrin-selenium, 40 μg/
mL L-proline, 50 μg/mL ascobate-2-phosphate, 10 ng/mL
transforming growth factor-beta 1 (TGFβ1), 100 U/mL
penicillin sodium, 100 U/mL streptomycin sulfate, and
0.25 μg/mL amphotericin B—for 28 days before fixing in
10% PBS. Cultures were stained for mineral by using von
Kossa’s method followed by proteoglycan staining with
Alcian Blue.
Nitrite measurements
Nitrite, as a reflection of NO production, was measured
in cell culture supernatant by using the Griess Reagent
system (Promega, Madison, WI, USA) in accordance with
the instructions of the manufacturer.
Western blotting
Whole lysates were prepared from cultures that had been
left untreated, treated with LPS (100 ng/mL), or treated
with both LPS and IFNγ (250 ng/mL) for 24 hours. Pro-
tein concentrations were determined by bicinchoninic
acid assay. Protein samples (50 μg per lane) were sepa-
rated by SDS-PAGE and transferred to polyvinylidene
fluoride membrane. After blocking in 5% milk in Tris-
buffered saline with 0.1% tween-20 (TBST), membranes
were incubated overnight with iNOS (#2977) primary
antibody from Cell Signaling Technology (Danvers, MA,
USA) diluted 1:500 with 5% bovine serum albumin (BSA)
in TBST. After incubation with anti-rabbit IgG horse-
radish peroxidase-tagged secondary antibody from Santa
Cruz Biotechnology (Santa Cruz, CA, USA), bands
were visualized by using enhanced chemiluminescence.
To normalize protein loading, blots were also probed
for β-actin expression.
Secreted cytokine and chemokine measurements
The Proteome Profiler Array, mouse cytokine array panel
A, from R&D Systems (Minneapolis, MN, USA) was used
to screen for changes in secreted cytokines and chemo-
kines in MΦ cells and co-cultures with and without treat-
ment with ox-LDL. TNFα and IL-6 were measured in
culture supernatants by using Ready-set-Go enzyme-linked
immunosorbent assay (ELISA) kits from eBioscience (San
Diego, CA, USA).
Statistical analyses
Data was analyzed by using two-way analysis of variance.
Post hoc test P values were adjusted by using the Bonferroni
correction. All tests were two-tailed, and a nominal signifi-
cance level of 0.05 was used.
Results
Characterization of the aorta-derived mesenchymal
progenitor (mAo) cells and the bone marrow-derived
macrophage (MΦ) cells
Mesenchymal progenitor cells were previously isolated
from mouse aorta (mAo) and cloned by high prolifera-
tive capacity. We have demonstrated their ability to
undergo osteoblast and adipocyte differentiation and
their high expression of vimentin, fibronectin, and β1-
integrin (CD29) [14]. To characterize these cells further,
we used flow cytometry to examine their expression of
multipotent stromal cells also known as MSC-associated
cell surface markers and tested their ability to differenti-
ate into chondrocytes. The mAo cells express the MSC-
associated cell surface antigens CD29, CD44, CD105,
CD106, and Sca-1 but not CD73 and are capable of min-
eralizing chondrogenic differentiation as demonstrated
by positive Alcian Blue/von Kossa staining. They are nega-
tive for the hematopoietic cell surface antigens CD11b
and CD45 (Additional file 1: Figure S1A and C). To con-
firm that our macrophage isolation procedure produces a
homogeneous population of cells, we demonstrate that
they express the monocyte/macrophage intracellular
marker MOMA-2 and are resistant to sodium fluoride in-
hibition of non-specific esterase stain (Additional file 1:
Figure S1B and C).
mAo cells in culture with MΦ cells contribute to local NO
production in response to LPS and LPS/IFNγ
We first examined NO production in response to in-
flammatory mediators by mAo and macrophage cells
alone and in co-culture. NO production is a hallmark of
the inflammatory M1 macrophage [16] but is also pro-
duced by some MSC populations to control T-cell prolif-
eration and chemotaxis [17,18]. Untreated mAo cells,
MΦ cells, and co-cultures produce undetectable levels
of NO. When mAo cells were co-cultured with MΦ cells
and exposed to LPS, they synergistically produced NO
greater than 10-fold above either mAo or MΦ cells
cultured alone. Co-cultures exposed to LPS and IFNγ
in combination produced NO in an additive manner
(Figure 1A,B).
To demonstrate the contribution of the mAo cells to
the significantly elevated NO, we used co-cultures of mAo
and TLR4-deficient splenic macrophage (TLR4-MΦ)
cells which have a deficient inflammatory response to
LPS [19]. As expected, TLR4-MΦ cells do not respond
to LPS with an increase in NO. However, TLR4-MΦ/mAo
cell co-cultures exposed to LPS demonstrate a significant
increase in NO similar to the MΦ/mAo cell co-cultures
(Figure 1A, B). Unexpectedly, TLR4-MΦ cells respond to
LPS in the presence of IFNγ with significant NO produc-
tion. In macrophage cells, Toll-like receptor-2 (TLR2) is
upregulated by IFNγ and is capable of responding to LPS
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[20]. Therefore, it is likely that through upregulation and
signaling through TLR2, the TLR4-MΦ cells produce NO
in response to LPS/IFNγ in combination. Western blot
demonstrated the upregulation of iNOS in association with
elevated NO production, confirming activity of this enzyme
as the source of NO (Figure 1C).
To determine whether cell-cell contact is required for
the production of NO in MΦ/mAo cell co-cultures after
activation, we used a transwell culture system (Figure 2A).
mAo and MΦ cell populations were grown separated by a
0.4-μM filter which allows the passage of soluble factors
between cell types but does not allow cell-cell contact.
Both cell types were exposed to LPS or LPS and IFNγ, and
the supernatants collected from the transwell compart-
ment and the well compartment were analyzed for NO
content separately with the expectation that NO concen-
trations in the compartments would be equivalent. Our
results, however, reflect a gradient in NO diffusion, with
NO concentrations greater near the MΦ cells in the trans-
well compartment. Regardless of the gradient, co-cultures
grown in direct contact produce significantly greater NO
than found in either compartment of the transwell culture
system (Figure 2B).
Interaction with mAo cell progenitors increases ox-LDL
uptake by MΦ cells
Vascular disease is associated with elevated levels of
LDL and increased uptake of oxidized-LDL (ox-LDL) by
MΦ cells [21]. To determine the effect that contact with
the mAo cell progenitor has on MΦ cell uptake of ox-
LDL, we exposed mAo and MΦ cells alone and in co-
culture to ox-LDL. Ox-LDL uptake by MΦ cells was
confirmed by Oil Red O staining, followed by photo-
micrograph and spectrophotometric analysis of extracted
stain (Figure 3). No significant uptake of ox-LDL by mAo
cells cultured alone was observed (Figure 3A,B), and a sig-
nificant 1.5-fold increase in lipid staining was found in
MΦ/mAo cell co-cultures compared with MΦ cells cul-
tured alone (Figure 3C-G).
MΦ and mAo cell progenitor interaction restores
ox-LDL-suppressed local NO production in response to
LPS and LPS/IFNγ
Next, we sought to determine the influence of the mAo
cells on MΦ cell production of NO after ox-LDL uptake.
The uptake of ox-LDL by MΦ cells is associated with
suppression of their NO production in response to in-
flammatory mediators [22] and our results confirm this
finding. NO production is significantly reduced in MΦ
cell cultures exposed to ox-LDL upon activation with LPS
and LPS/IFNγ, approximately 5- and 1.8-fold, respectively
(Figure 4A). However, LPS- and LPS/IFNγ-induced NO
production in MΦ/mAo cell co-cultures returns to syner-
gistic or additive levels found in the absence of ox-LDL
(Figure 4A).
Figure 1 mAo cells in culture with MΦ cells contribute to local NO production in response to LPS and LPS/IFNγ. Nitrite production as a measure
of NO in culture supernatants of mAo, MΦ, and splenic MΦ cells derived from TLR4-deficient mice (TLR4-MΦ) treated (A) with LPS (100 ng/mL)
and (B) with LPS (100 ng/mL) + IFNγ (250 ng/mL) alone and in co-culture. Data are presented as mean ± standard error of the mean and are
representative of three experiments each with n = 4. *Significantly different from MΦ cells alone; #significantly different from TLR4-MΦ cells alone.
(C) Representative Western blots from a separate experiment showing iNOS expression. Whole lysates were prepared from cultures, and 50 μg
was loaded per lane. β-actin was used to control for protein loading. IFNγ, interferon-gamma; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide;
MΦ, bone marrow-derived macrophage; mAo, mouse aorta-derived mesenchymal progenitor; MSC, mesenchymal stem cell; NO, nitric oxide; TLR4, Toll-like
receptor-4; TLR4-MΦ, Toll-like receptor-4-deficient macrophage.
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We used the TLR4-MΦ cells to determine the contri-
bution of the mAo cells to NO production in ox-LDL-
treated MΦ/mAo cell co-cultures. NO production was
at similar levels in TLR4-MΦ/mAo and MΦ/mAo cell
co-cultures after exposure to LPS, confirming the contri-
bution of the mAo cells (Figure 4B). Again, the TLR4-
MΦ cells respond to LPS/IFNγ with significant NO
production, making it difficult to discern the contribu-
tion of the mAo cells.
To determine whether cell-cell contact is required for
co-culture effects on NO production, mAo and MΦ cells
exposed to ox-LDL were cultured together or separated
by a filter with the use of transwell inserts (Figure 4C).
NO production in ox-LDL-treated mAo and MΦ cell
cultures separated by a filter is significantly lower, approxi-
mately 17-fold with LPS activation and approximately 3.8-
fold with LPS/IFNγ activation, than co-cultures without a
filter, indicating that cell-cell contact is required to recover
production of NO (Figure 4C). We again found a gradient
in NO concentration through the separate analysis of each
compartment. Therefore, we used conditioned medium
experiments to ensure that the cells were being exposed
to the soluble factors produced by the opposing cell type
after activation. We incubated mAo cell cultures with the
conditioned medium of activated ox-LDL-treated MΦ
Figure 2 Cell-cell contact is required for the production of NO in
MΦ/mAo cell co-cultures. MΦ and mAo MSCs were grown sepa-
rated by a 0.4-μm filter (A) and activated with LPS (100 ng/mL) or
with LPS (100 ng/mL) + IFNγ (250 ng/mL) for 24 hours. Supernatant
of the mAo cells grown in the well and supernatant from the MΦ
cells grown in the transwell were analyzed for NO content separately
(B). Data are presented as mean ± standard error of the mean and
are representative of three experiments each with n = 4. *Significantly
different from both transwell and well compartments. IFNγ,
interferon-gamma; LPS, lipopolysaccharide; MΦ, bone marrow-derived
macrophage; mAo, mouse aorta-derived mesenchymal progenitor;
MSC, mesenchymal stem cell; NO, nitric oxide.
Figure 3 Interaction with mAo cells increases ox-LDL uptake by MΦ
cells. Photomicrographs of Oil Red O stained cultures without (left
frames) and with (right frames) ox-LDL (50 μg/mL) exposure for
24 hours. mAo cell cultures in (A) and (B), MΦ cell cultures in (C)
and (D), and MΦ/mAo cell co-cultures in (E) and (F) are shown.
Scale bar = 100 μM. (G) The spectrophotometric analysis of extracted
Oil Red O stain. Data are presented as mean ± standard error of the
mean and are representative of three experiments each with n = 4.
*Significantly different from non-ox-LDL-treated counterpart; #significantly
different from MΦ cells alone under same conditions. MΦ, bone
marrow-derived macrophage; mAo, mouse aorta-derived
mesenchymal progenitor; OD, optical density; ox-LDL, oxidized
low-density lipoprotein.
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Figure 4 mAo and MΦ cell interaction restores ox-LDL-suppressed local NO production in response to LPS and LPS/IFNγ. Nitrite production is
shown as a measure of NO in culture supernatants of MΦ cells (A) and TLR4-MΦ cells (B) alone and in co-culture with mAo cells after being
treated with or without ox-LDL (50 μg/mL) for 24 hours and then activated with LPS (100 ng/mL) or with LPS (100 ng/mL) + IFNγ (250 ng/mL) for
24 hours. MΦ cells after being exposed to ox-LDL (50 μg/mL) for 24 hours were also cultured in transwells with mAo cells present in the well as
depicted. Both MΦ cells in the transwell and mAo cells in the well were activated with LPS or LPS + IFNγ, and supernatants from the transwell
and well were assayed for nitrate content separately (C). Ox-LDL-treated mAo and MΦ cells were exposed to CM (collected after ox-LDL exposure
and LPS and LPS + IFNγ (L/I) activation) from the opposing cell type. NO levels in the CM were subtracted from the supernatant values, and the
net production is presented in (D). Data are presented as mean ± standard error of the mean and are representative of three experiments each
with n = 4. *Significantly different from MΦ or TLR4-MΦ cells alone under same conditions; #significantly different from non-ox-LDL-treated
counterpart; †significantly different from well and transwell supernatant; ‡significantly different from cultures exposed to CM. CM, conditioned medium;
IFNγ, interferon-gamma; LPS, lipopolysaccharide; MΦ, bone marrow-derived macrophage; mAo, mouse aorta-derived mesenchymal progenitor; MSC,
mesenchymal stem cell; NO, nitric oxide; ox-LDL, oxidized low-density lipoprotein; TLR4-MΦ, Toll-like receptor-4-deficient macrophage.
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cells and incubated ox-LDL-treated MΦ cells to the con-
ditioned medium of activated mAo cells and measured
the net NO production (Figure 4D). In line with the trans-
well cultures, NO produced by cultures exposed to condi-
tioned medium was significantly less than when mAo and
MΦ cells were cultured in direct contact.
MΦ and mAo cell progenitor interaction restores
ox-LDL-suppressed local LPS- and LPS/IFNγ-induced
cytokine/chemokine production
Data are contradictory regarding inflammation-induced
cytokine production in ox-LDL-laden MΦ cells. Some
studies demonstrate a suppressed inflammatory response
[23-25], whereas others claim that ox-LDL exposure en-
hances production of cytokines [26,27]. As an initial
screen for co-culture-induced changes in the LPS- and
LPS/IFNγ-responsive cytokine/chemokine secretion pro-
file of lipid-laden MΦ cells, we used the mouse cytokine
Proteome Profiler (R&D Systems). After uptake of ox-
LDL, MΦ cell secretion of a number of growth factors,
cytokines, and chemokines was reduced upon LPS and
LPS/IFNγ exposure (Figure 5). MΦ/mAo cell interaction
restored secretion of several chemokines involved in the
summoning of the adaptive immunity—that is, CXCL2,
Figure 5 MΦ and mAo cell interaction restores ox-LDL-suppressed local LPS- and LPS/IFNγ-induced cytokine/chemokine production. Mouse cytokine
Proteome Profiler immunoblots (A) and corresponding graphs of densitometry results (B, C) demonstrate changes in cytokine/chemokine levels in
supernatants of MΦ cells, MΦ cells exposed to ox-LDL (50 μg/mL), and MΦ cells exposed to ox-LDL in co-culture with mAo cells. Cultures were activated
with LPS (100 ng/mL) and LPS (100 ng/mL) + IFNγ (250 ng/mL) for 24 hours. Numbered boxes highlight cytokine/chemokines whose expression is
changed with treatments in (A) and correspond with cytokine/chemokine numbers in (B) and (C). Circles highlight internal control spots used to normalize
densitometric data. Graphs in (B) and (C) present the changes in spot density when compared with untreated MΦ cells (Fold Δ/UNT MΦ). The blot of the
untreated MΦ cells can be viewed in Additional file 2: Figure S2 along with the overlay. The key for the spots can be found in Additional file 3. CXCL,
chemokine (C-X-C motif) ligand; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte/macrophage colony-stimulating factor;
IFNγ, interferon-gamma; IL, interleukin; LPS, lipopolysaccharide; MΦ, bone marrow-derived macrophage; mAo, mouse aorta-derived
mesenchymal progenitor; MCP, monocyte chemoattractant protein; ox-LDL, oxidized low-density lipoprotein; RANTES, regulated on activation, normal
T-cell expressed and secreted; sICAM1, soluble intercellular adhesion molecule-1; TNFα, tumor necrosis factor-alpha.
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CXCL9, CXCL10, and RANTES (regulated on activation,
normal T-cell expressed and secreted). Although these
and other changes in cytokine, chemokine, and growth
factor secretions were observed—that is, co-cultures fa-
vored secretion of granulocyte colony-stimulating factor
(G-CSF) over granulocyte/macrophage colony-stimulating
factor (GM-CSF) as well as MCP-5 over MCP-1—we fo-
cused on the cytokines IL-6 and TNFα for this study. Pro-
duction of these inflammatory cytokines is associated with
vascular disease, and their significant secretion in response
to LPS and LPS/IFNγ was restored by MΦ/mAo cell
co-culture (Figure 5, Additional file 2: Figure S2 and
Additional file 3).
With exposure to ox-LDL, MΦ and mAo cell interaction
restores LPS- and LPS/IFNγ-induced IL-6 secretion which
is contributed by the mAo cell progenitor
Next, we confirmed the cytokine Proteome Profiler re-
sults for IL-6 and determined the contribution of the
mAo cells to the restoration of local IL-6 secretion in
ox-LDL-exposed cultures by using ELISA. In mAo cell
cultures, LPS- and LPS/IFNγ-induced secretion of IL-6
is nominal compared with MΦ and MΦ/mAo cell cul-
tures (Figure 6A). The interaction of mAo and MΦ cells
results in a significant increase in production of IL-6 in
response to LPS (approximately 2-fold increase) and LPS/
IFNγ (approximately 3.5-fold increase) when compared
with MΦ cells alone (Figure 6A). After uptake of ox-LDL,
LPS- and LPS/IFNγ-induced IL-6 production is signifi-
cantly suppressed in MΦ cell cultures by 167- and 61-
fold, respectively. Under the same conditions, interaction
of MΦ-mAo cells returns IL-6 secretion to levels observed
in MΦ cell cultures not treated with ox-LDL (Figure 6A).
To determine whether the mAo cells directly contrib-
ute to the LPS- and LPS/IFNγ-induced IL-6 production
in the presence and absence of ox-LDL, we used TLR4-
MΦ and TLR4-MΦ/mAo cell cultures. As expected, ac-
tivated TLR4-MΦ cells secrete IL-6 at levels significantly
lower, more than 900-fold lower with LPS activation and
35-fold lower with LPS/IFNγ activation, than those of MΦ
cell cultures not deficient in TLR4 (Figure 6B). However, in
TLR4-MΦ/mAo cell cultures, IL-6 production is signifi-
cantly increased and in the presence of ox-LDL remains at
37.5% and 56% of the levels measured in the absence of
ox-LDL after LPS and LPS/IFNγ exposure, respectively.
To distinguish between a soluble factor and a direct
cell contact-mediated mechanism, MΦ and mAo cells
were separated by a transwell filter insert, treated with
ox-LDL, and activated with LPS and LPS/IFNγ. Without
direct contact, IL-6 production by MΦ and mAo cells is
commensurate with the levels found when they are cul-
tured alone (Figure 6C), indicating the involvement of a
direct contact mechanism. Again, to ensure that the cells
were being exposed to the soluble factors produced by the
opposing activated cell type, we used conditioned medium
experiments. mAo cell cultures incubated with the condi-
tioned medium of activated ox-LDL-treated MΦ cells and
ox-LDL-treated MΦ cells incubated with the conditioned
medium of activated mAo cells produced IL-6 at signifi-
cantly lower levels than when the cells are in direct con-
tact, similar to the transwell cultures (Figure 6D).
With exposure to ox-LDL, MΦ and mAo cell progenitor
interaction restores significant LPS- and LPS/IFNγ-induced
TNFα production by MΦ cells
We also confirmed the cytokine Proteome Profiler results
for TNFα and determined the contribution of the mAo
cells to the restoration of local TNFα secretion in ox-
LDL-exposed cultures by using ELISA. MSCs have been
reported to be unable to produce TNFα [28,29], and we
confirmed these findings in the mAo cell cultures. The
TNFα protein was undetectable in the supernatant of
these cells, and transcript expression was also out of de-
tection range in mAo cells with or without treatment with
inflammatory mediators (Additional file 4). After uptake
of ox-LDL, LPS- and LPS/IFNγ-induced TNFα production
is significantly suppressed in MΦ cell cultures by 155- and
4.6-fold, respectively. Under the same conditions, inter-
action of MΦ and mAo cells returns TNFα to 21.7% and
63% of levels observed in non-ox-LDL-treated MΦ/mAo
cell co-cultures after treatment with LPS or LPS/IFNγ,
respectively (Figure 7A).
To confirm the expectation that mAo cells do not dir-
ectly contribute to the LPS- and LPS/IFNγ-induced TNFα
production in the presence and absence of ox-LDL, we
used TLR4-MΦ and TLR4-MΦ/mAo cell cultures. As ex-
pected, activated TLR4-MΦ cells secrete TNFα at levels
significantly lower, more than 150-fold lower with LPS
and more than 10-fold lower with LPS/IFNγ activation,
than those of MΦ cell cultures not deficient in TLR4
(Figure 7B). In TLR4-MΦ/mAo cell cultures under condi-
tions of suppressed MΦ cell response (that is, in the pres-
ence of ox-LDL and TLR4 deficiency), TNFα production,
unlike IL-6 production, is not significantly increased above
TLR4-MΦ cells alone.
The transwell system was again used to determine
whether the MΦ-mAo cell interaction effect on TNFα
secretion is dependent upon a soluble factor or a direct
cell contact-mediated mechanism. Without direct con-
tact with mAo cells, TNFα production by MΦ cells is
commensurate with the level found when they are cultured
alone (Figure 7C), indicating the involvement of a direct
contact mechanism. These data were also confirmed with
conditioned medium studies (Figure 7D).
Discussion
It is well known that mesenchymal progenitors can sup-
press immune responses [1]. However, these cells can
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also support inflammatory responses and therefore have
been termed ‘sensors and switchers’ of inflammation
[17,18]. In fact, a recent paradigm suggests a polarization
similar to that of leukocyte activation in which both pro-
inflammatory and immunosuppressive mesenchymal pro-
genitor phenotypes can develop dependent upon the
environment [12,28]. According to this paradigm, mAo
cells, when in direct contact with MΦ cells and exposed
to ox-LDL and inflammatory mediators, are pro-
inflammatory. mAo cells contribute to local production
of both NO and IL-6 and enhance ox-LDL uptake by
macrophage cells. MΦ cells exposed to ox-LDL experi-
ence suppressed secretion of NO, IL-6, and TNFα in re-
sponse to inflammatory mediators, and the interaction
with mAo cells restored significant secretion of these in-
flammatory markers. mAo cells contribute to the restor-
ation of the inflammatory response both directly through
production of NO and IL-6 and indirectly by promoting
TNFα secretion by the MΦ cells. Both transwell and con-
ditioned medium experiments suggest a direct contact
mechanism for this restoration.
It should be noted that data regarding the inflammatory
response of lipid-laden MΦ cells are conflicting. Older
studies using RAW 264.7 MΦ, murine bone marrow-
derived, and peritoneal MΦ cells demonstrate a suppres-
sion of inflammatory cytokine secretion after ox-LDL
exposure [21-25]. More recently, others have demon-
strated that ox-LDL loading enhances the inflammatory
response of MΦ cells [26,27]. The study by Groeneweg and
colleagues [26], like our study, used bone marrow-derived
MΦ cells from C57BL/6 mice which were propagated in
medium supplemented with L-929 fibroblast conditioned
medium. They found that priming MΦ cells with ox-LDL
increased their production of IL-6 and TNFα in response
to LPS. Yet in our hands, these cells experience a signifi-
cantly suppressed response to LPS and LPS/IFNγ after ox-
LDL loading. Perhaps this discrepancy may be explained by
the conditions in which the MΦ cell cultures were activated
with the inflammatory mediators. Our cultures were ex-
posed to LPS and LPS/IFNγ in a serum-free medium
supplemented with 0.2% BSA, but in the study by
Groeneweg and colleagues, the LPS was added to
medium supplemented with FBS. The response to in-
flammatory cues by MΦ cells in a lipid-laden environ-
ment needs further exploration.
The criteria for applying the designation of multipo-
tent mesenchymal stromal cells also known as MSCs
have been an area of contention in mesenchymal pro-
genitor research. In 2006, the Mesenchymal and Tissue
Stem Cell Committee of the International Society for
Cellular Therapy published a position paper outlining
minimum criteria for the MSC designation in human
cell populations [30]. For mouse cells, however, no clear
criteria have emerged, and there are many differences in
MSC surface antigen expression between mouse and hu-
man cells [31]. There is also a great variation in reported
MSC surface antigen expression, and many new poten-
tial identifying antigens are continually emerging [32].
Therefore, the concept of MSCs has become increasingly
ambiguous. The mAo cells used in this study have the
potential to differentiate into osteoblast, adipocyte, and
chondrogenic lineages and express several surface anti-
gens associated with mouse MSCs. However, the ‘stem-
ness’ of these cells has not been completely characterized;
hence, we have used the term mAo cell progenitor.
Many recent studies explore the relationship between
heterogeneity in surface antigen expression and heterogen-
eity in functional properties among MSCs. For example,
MSCs isolated from adipose (AdMSCs) are heterogenic
in CD105 (endoglin) expression, and CD105+ AdMSCs
are functionally distinct from those that are CD105−
[33]. In line with this study, surface antigen expression
in MSCs and more differentiated mesenchymal cell pop-
ulations also appears closely associated with immuno-
regulatory function. mAo cell progenitors and vascular
smooth muscle cells in contact with monocytes are pro-
inflammatory and are CD105+/CD73− [34-36], whereas
bone marrow-derived MSCs (BMMSCs) and AdMSCs
are CD105−/CD73+ and promote the differentiation of
the anti-inflammatory macrophage [33,37]. CD105+
AdMSCs have a reduced capacity to regulate T-cell
proliferation [33], and CD73 or ecto-5′-nucleotidase
(See figure on previous page.)
Figure 6 With exposure to ox-LDL, MΦ and mAo cell interaction restores LPS- and LPS/IFNγ-induced IL-6 secretion which is contributed by the
mAo cells. Secreted IL-6 measured in culture supernatants of MΦ cells (A) and TLR4-MΦ cells (B) alone and in co-culture with mAo cells after being
treated with or without ox-LDL (50 μg/mL) for 24 hours and then activated with LPS (100 ng/mL) or with LPS (100 ng/mL) + IFNγ (250 ng/mL) is
shown. MΦ cells after being exposed to ox-LDL (50 μg/mL) for 24 hours were also cultured in transwells with mAo cells present in the well as depicted
in (C). Both MΦ cells in the transwell and mAo cells in the well were activated with LPS or LPS + IFNγ, and supernatants from the transwell and well
compartments were assayed for IL-6 content separately (C). Ox-LDL-treated mAo and MΦ cells were exposed to CM (collected after ox-LDL exposure
and LPS and LPS + IFNγ (L/I) activation) from the opposing cell type. IL-6 levels in the CM were subtracted from the supernatant values, and the net
production is presented in (D). Data are presented as mean ± standard error of the mean and are representative of three experiments each with n = 4.
*Significantly different from MΦ or TLR4-MΦ cells alone under same conditions; #significantly different from non-ox-LDL-treated counterpart;
†significantly different from well and transwell supernatant; ‡significantly different from cultures exposed to CM. CM, conditioned medium; IFNγ,
interferon-gamma; IL-6, interleukin-6; LPS, lipopolysaccharide; MΦ, bone marrow-derived macrophage; mAo, mouse aorta-derived mesenchymal
progenitor; MSC, mesenchymal stem cell; ox-LDL, oxidized low-density lipoprotein; TLR4-MΦ, Toll-like receptor-4-deficient macrophage.
Evans et al. Stem Cell Research & Therapy  (2015) 6:56 Page 11 of 15
Figure 7 (See legend on next page.)
Evans et al. Stem Cell Research & Therapy  (2015) 6:56 Page 12 of 15
catalyzes the conversion of 5′-AMP to adenosine and
plays an important role in suppressing inflammation
[38]. Expression of CD105 and the lack of CD73 in
mAo cells could be why they, unlike BMMSCs and
AdMSCs, do not suppress but support the inflamma-
tory response of macrophage cells. CD105 expression
is elevated in atherosclerotic plaque [39], and inactiva-
tion of CD73 promotes atherogenesis in apolipoprotein
E-deficient mice [38], correlating our in vitro data to
data from in vivo studies.
We used the TLR-4-deficient splenic macrophage
(TLR4-MΦ) cells, which are unresponsive to LPS, to de-
termine the contribution of the mAo cell progenitor to
the inflammatory response. However, in the presence of
IFNγ, the TLR4-MΦ cells were capable of responding to
LPS and therefore the precise contribution from the
mAo cell progenitor in the presence of IFNγ remains to
be determined. In macrophage cells, TLR2 is upregu-
lated by IFNγ and can be activated by LPS [20]. There-
fore, it is likely that through upregulation and signaling
through TLR2, the TLR4-MΦ cells produce inflamma-
tory mediators in response to LPS/IFNγ in combination.
However, transwell and conditioned medium experi-
ments confirm that cell contact between the mAo cell
progenitors and the macrophage cells is required for the
inflammatory response in the presence of LPS/IFNγ.
In the indirect co-culture studies, analysis of super-
natant from the transwell and the well compartments
separately revealed the presence of a diffusion gradient
between the compartments after 24 hours of incubation.
To ensure that the cells were exposed to secreted sol-
uble factors at the concentrations that would be present
if the cells were in immediate proximity, we used condi-
tioned medium experiments. Although our findings were
confirmed, the presence of a gradient identifies a potential
limitation to using the transwell for indirect co-culture
studies.
It is clear that the MΦ-mAo cell interaction contrib-
utes to the inflammatory response; however, the roles of
NO, IL-6, and TNFα in the progression of vascular
disease remain unclear. Elevated NO levels can contrib-
ute to local tissue damage and macrophage apoptosis
[40,41], but NO can also suppress LDL oxidation
[42-45]. Exogenous IL-6 treatment in apolipoprotein E-
deficient (ApoE−/−) mice results in an enhancement of
lesions [46], but a lifetime of IL-6 deficiency in this
same animal model leads to a similar result [47]. IL-6
also protects human macrophages from cellular choles-
terol accumulation through enhancing ATP-binding
cassette transporter 1 (ABCA1)-mediated cholesterol
efflux [48]. Exposure to TNFα for 24 hours reduces
scavenger receptor expression in macrophage and sub-
sequent ox-LDL uptake [49,50]. On the other hand,
TNFα exposure at 1 to 10 ng/mL is associated with re-
ductions in macrophage efferocytosis [51]. Therefore,
synergism in the production of IL-6, TNFα, and NO in
the early stages of vascular disease could be acting in
concert against further atherosclerotic progression by
reducing local LDL oxidation, reducing ox-LDL uptake
through suppression of scavenger receptors, and enhan-
cing cholesterol efflux. However, in later stages, this con-
tinued synergism could lead to increased macrophage
apoptosis, decreased efferocytosis, and subsequent plaque
instability.
In lipid-laden MΦ cell cultures, the secretion of several
chemokines was suppressed in response to inflammatory
mediators but was restored upon co-culture with mAo
cells. These (C-X-C motif ligand) chemokines—CXCL2,
CXCL9, CXCL10, and CCL5 (RANTES)—play roles in
leukocyte recruitment and interfacing the innate with the
inflammatory adaptive immunity [9]. It is also interesting
to note the switch from MCP-1 secretion in activated
macrophage cultures to MCP-5 secretion in activated co-
cultures of MΦ and mAo cells. MCP-5 is the mouse
orthologue to MCP-1 in humans and is expressed in
ovalbumin-treated macrophage and airway smooth
muscle cells [52]. Although MCP-5 is chemotactic for
monocytes, lymphocytes, and eosinophils, among lympho-
cytes it preferentially attracts the B1 B-lymphocyte in vitro
[52]. The B1 B-lymphocyte has been characterized as anti-
(See figure on previous page.)
Figure 7 With exposure to ox-LDL, MΦ and mAo cell interaction restores significant LPS- and LPS/IFNγ-induced TNFα production by MΦ cells.
Secreted TNFα measured in culture supernatants of MΦ cells (A) and TLR4-MΦ cells (B) alone and in co-culture with mAo cells after being treated
with or without ox-LDL (50 μg/mL) for 24 hours and then activated with LPS (100 ng/mL) or with LPS (100 ng/mL) + IFNγ (250 ng/mL) is shown.
MΦ cells after being exposed to ox-LDL (50 μg/mL) for 24 hours were also cultured in transwells with mAo cells present in the well as depicted
in (C). Both MΦ cells in the transwell and mAo cells in the well were activated with LPS or LPS + IFNγ, and supernatants from the transwell and
well were assayed for TNFα content separately (C). Ox-LDL-treated mAo and MΦ cells were exposed to CM (collected after ox-LDL exposure and
LPS and LPS + IFNγ (L/I) activation) from the opposing cell type. TNFα levels in the CM were subtracted from the supernatant values, and the net
production is presented in (D). Data are presented as mean ± standard error of the mean and are representative of three experiments each with
n = 4. *Significantly different from MΦ or TLR4-MΦ cells alone under same conditions; #significantly different from non-ox-LDL-treated counterpart;
†significantly different from well and transwell supernatant; ‡significantly different from cultures exposed to CM. CM, conditioned medium; IFNγ,
interferon-gamma; LPS, lipopolysaccharide; MΦ, bone marrow-derived macrophage; mAo, mouse aorta-derived mesenchymal progenitor; MSC,
mesenchymal stem cell; ox-LDL, oxidized low-density lipoprotein; TLR4-MΦ, Toll-like receptor-4-deficient macrophage; TNFα, tumor
necrosis factor-alpha.
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atherogenic [53]. The role of MCP-5 in vascular disease
warrants further investigation.
Conclusions
The interaction between macrophage cells and mAo cell
progenitors under inflammatory conditions is synergistic
in the secretion of the NO, IL-6, and TNFα inflamma-
tory markers. After uptake of ox-LDL, MΦ cell inter-
action with mAo cells re-establishes the inflammatory
response as well as the interface between the innate and
adaptive immunities. Early during vascular disease pro-
gression, this may be beneficial, but continued support
of inflammatory activity in later stages of disease could
lead to irreparable damage. The vascular mesenchymal
progenitor and its contact with lipid-laden macrophage
represent an additional target for therapeutics in chronic
vascular inflammation.
Additional files
Additional file 1: Figure S1. Characterization of the aorta-derived
progenitor (mAo) cell line and bone marrow-derived macrophage (MΦ).
Flow cytometry results demonstrate expression of mesenchymal stem cell
(MSC)-associated surface antigens in the mAo cell cultures (A) and the
expression of the MOMA-2 monocyte/macrophage-associated intracellular
antigen by the MΦ cultures (B). (C) Photomicrographs of MΦ cultures
stained with non-specific esterase (NSE) in the presence of fluoride and
counterstained with hematoxylin to demonstrate the nuclei. mAo cells were
stained with Alcian Blue/von Kossa (AB/VK) stain after culture in
chondrogenic conditions.
Additional file 2: Figure S2. Proteome Profiler cytokine/chemokine
blot of untreated MΦ culture which was used as a baseline to analyze
data presented in Figure 5. Densitometric data from mouse cytokine
Proteome Profiler immunoblots shown in Figure 5 were compared with
densitometric analysis of the untreated MΦ blot shown here (A). (B) The
overlay of coordinates. The key is found in Additional file 3. MΦ, bone
marrow-derived macrophage.
Additional file 3: The key for the Proteome Profiler coordinates
found in Additional file 2: Figure S2.
Additional file 4: Secreted tumor necrosis factor-alpha (TNFα)
protein and TNFα transcript are below level of detection in mAo cell
cultures. An Excel file shows standard curves and assay results from
enzyme-linked immunosorbent assay (ELISA) and real-time polymerase
chain reaction (PCR) for TNFα expression in mAo cell cultures. mAo, mouse
aorta-derived mesenchymal progenitor.
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